How Has Survival Changed in Urothelial Cancer Before and After Immunotherapy and ADCs?

Real-World Data on Immune Checkpoint Inhibitors and Antibody-Drug Conjugates

🔍 Why Does It Matter?

• Urothelial cancers arise primarily in the bladder , but also in the ureters, renal pelvis and urethra . More than 90% arise in the bladder .
• Worldwide, approximately 573,000 new bladder cancer cases occur annually, with nearly 213,000 deaths.
• Bladder cancer is among the 10 commonest cancers in men, with high mortality and a tendency to recur.

Approximately 10-15% have metastatic (Stage 4) disease at diagnosis . A substantial proportion initially diagnosed with localized or non-muscle-invasive disease may later develop metastases; in muscle-invasive disease this may reach 50% . Overall, around 30-40% of bladder cancer patients face distant metastasis during their lives.

Metastatic urothelial cancer (mUC), including bladder cancer, generally has a poor prognosis. With conventional chemotherapy, 5-year survival was below 5%. Immune checkpoint inhibitors and antibody-drug conjugates (ADCs) could change this, but their effects outside clinical trials, in everyday practice, were less clear.

📊 JAMA Network Openpublished a large retrospective analysis on 9 July 2025 that provides an answer: New immunotherapies and ADCs significantly improve overall survival.

🔬 Study Details

• Data Source: US Flatiron Health electronic health records database
• Period: 8,955 patients starting treatment in 2011–2023
• Follow-Up: Through 30 September 2024
• Treatment Eras Included:
  1. Before immunotherapy (2011–2016) – predominantly chemotherapy
  2. After immunotherapy, before ADCs (2017–2019) – immunotherapy introduction
  3. After ADC introduction (2020–2023) – modern era including ADCs

❗ Patients receiving investigational trial drugs or no treatment were excluded.

NOTE: The main ADC used in urothelial cancer is nectin-4-targeting enfortumab vedotin (brand: Padcev). Less commonly, Trop-2-targeting sacituzumab govitecan (Trodelvy) is also used in selected patients.

📈 Survival Data

✅ 3-Year Overall Survival Rates:

🔹 These findings represent an 8.4% absolute and 44% relative increase .

🕒 Median Overall Survival:

• 2011–2016: 11.1 months
• 2020–2023: 13.6 months (significant difference, p < 0.001)

📌 What Does the Study Mean?

The study demonstrates benefits not only in clinical trials but also in real-world practice , where new-generation treatments offer substantial survival advantages to metastatic urothelial cancer patients.

In Particular:

• The contribution of ADCs such as enfortumab vedotin is evident.
• Data on combinations such asPadcev + Keytruda, pairing an ADC with immunotherapy, are also expected in the near future.

⚠️ Limitations

• Flatiron mainly covers community clinics , with limited academic-center data.
• The full effect of ADC + immunotherapy combinations, such as enfortumab + pembrolizumab (FDA approval: December 2023), could not yet be assessed.
• The retrospective design means treatment-related differences in patient characteristics could not be fully eliminated. Statistical methods, particularly inverse probability weighting, balanced these as far as possible.

💬 Conclusion

This large cohort strongly links survival improvements in metastatic urothelial cancer over the past decade to the introduction of immunotherapy and ADCs .

Over time, these developmentswill shape daily practice and clinical trial designs that can provide benchmarks for new treatment combinations.